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The effects induced by Apis mellifera venom (AMV), melittin-free AMV, fraction with
molecular mass < 10 kDa (F<10) or melittin in nociceptive and inﬂammatory pain models
in mice were investigated. Subcutaneous administration of AMV (2, 4 or 6 mg/kg) or
melittin-free AMV (1, 2 or 4 mg/kg) into the dorsum of mice inhibited both phases of
formaldehyde-induced nociception. However, F<10 (2, 4 or 6 mg/kg) or melittin (2 or 3 mg/
kg) inhibited only the second phase. AMV (4 or 6 mg/kg), but not F<10, melittin-free AMV
or melittin, induced antinociception in the hot-plate model. Paw injection of AMV (0.05 or
0.10 mg), F<10 (0.05 or 0.1 mg) or melittin (0.025 or 0.050 mg) induced a nociceptive
response. In spite of inducing nociception after paw injection, scorpion (Tityus serrulatus)
or snake (Bothrops jararaca) venom injected into the dorsum of mice did not inhibit
formaldehyde-induced nociception. In addition, AMV (6 mg/kg), but not F<10 (6 mg/kg) or
melittin (3 mg/kg), inhibited formaldehyde paw oedema. Concluding, AMV, F<10 and
melittin induce two contrasting effects: nociception and antinociception. AMV anti-
nociception involves the action of different components and does not result from non-
speciﬁc activation of endogenous antinociceptive mechanisms activated by exposure to
noxious stimuli.
 2011 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
In spite of thewide range of pharmacological classes and
drugs that have been used as analgesics for decades, there is
a continuing search for new alternatives, both because low
efﬁcacy or safety of many of them (Melnikova, 2010;
Woodcock, 2009). Among the new alternatives that havepis mellifera venom;
; s.c., subcutaneous;
or potential ankyrin.
; fax: þ55 031 3409
.M. Coelho).
lsevier OA license.been evaluated, products obtained fromanimals, plants and
microorganisms are promising. Many of them exhibit
a plethora of biological activities, including inhibition of
nociceptive behaviour in experimental models of pain.
Although the honeybee (Apis mellifera) sting induces local
pain and oedema (Vetter andVisscher,1998), theA.mellifera
venom (AMV) has traditionally been used to treat inﬂam-
matory diseases and to relieve pain (Lee et al., 2005; Son
et al., 2007). Various components of AMV have been iden-
tiﬁed, but there is not a consensus about their concentration.
The predominant component of the dried AMV is melittin
(40–50%), a peptide of 26 amino acid residues. Moreover,
many components with much lower concentration have
been identiﬁed including hyaluronidase, acid phosphatase,
L.A. Merlo et al. / Toxicon 57 (2011) 764–771 765apamin, mast cell degranulating peptide, adolapin, secapin,
minimine, phospholipase A2 (PLA2) histamine, glycosidase,
tertiapin, dopamine and carbohydrates (Gauldie et al.,1976;
Habermann, 1972; Nelson and O’Connor, 1968; Vetter and
Visscher, 1998; Vetter et al., 1999).
Among the multiple biological activities that have been
identiﬁed for AMV, inhibition of different aspects of the
inﬂammatory response is of great interest. AMV inhibits
oedema (Chang and Bliven, 1979) and nociception (Lee
et al., 2001) induced by carrageenan in rats. It also
inhibits inﬂammatory signs induced by Freund adjuvant in
rats (Kang et al., 2002; Lee et al., 2005) and the articular
inﬂammation induced by immune complex in rabbits
(Thomsen et al., 1984). Furthermore, AMV reduces the
production of inﬂammatory mediators in animal models of
arthritis induced by lipopolysaccharide (Lee et al., 2005).
Many mechanisms have been suggested to explain the
anti-inﬂammatory and antinociceptive effects induced by
AMV. It has been demonstrated that AMV inhibits cyclo-
oxygenase-2 expression (Jang et al., 2005; Nam et al., 2003)
and production of inﬂammatory cytokines (Nam et al.,
2003; Rekka et al., 1990) and nitric oxide (NO) (Jang
et al., 2005) induced by different inﬂammatory stimuli.
Furthermore, AMV increases cortisol production in
monkeys and dogs (Chang and Bliven, 1979; Kwon et al.,
2003), an effect that may also contribute to its anti-
inﬂammatory activity.
Some experimental studies with AMV components have
also been carried out. Melittin increases cortisol production
in monkey and dogs (Chang and Bliven, 1979; Kwon et al.,
2003), mast cell degranulating peptide inhibits inﬂamma-
tion induced by carrageenan (Martin and Hartter,1980) and
complete Freund adjuvant (Billingham et al., 1973),
whereas adolapin inhibits nociception, oedema and fever
induced by different inﬂammatory stimuli in rats
(Koburova et al., 1985; Shkenderov and Koburova, 1982).
Although different studies demonstrated the anti-
nociceptive effect induced by AMV and some of its
components, most of them evaluated this effect after their
injection in acupuncture points. The contribution of
different AMV components to its antinociceptive activity is
unclear, as the interpretation of the results is limited by
some drawbacks, including injection into acupuncture
points, lack of comparison of the activity of AMV and their
components in the same study and inadequate compari-
sons of results obtained from studies that used different
experimental models, animals and sources of the venom.
In the present study, we aimed to investigate the effects
induced by AMV, the fraction with molecular mass lower
than 10 kDa (F<10), melittin and melittin-free AMV in
experimental models of nociceptive and inﬂammatory pain
in mice. To achieve this objective, we injected the AMV or
its components into the dorsum (a non-acupoint) of the
animals, aiming to investigate a systemic effect.
2. Material and methods
2.1. Animals
Male Swiss mice (20–30 g) were used. The animals had
free access to food and water and were maintained ina roomwith a 12 h light–dark cycle for at least 3 days before
the experiments to allow acclimatization. The experiments
were carried out at a room temperature between 27 and
28 C, which corresponds to the thermoneutral zone for
rodents (Gordon, 1990). All experiments were performed
according to the ethical guidelines for investigation of
experimental pain in non-anaesthetised, non-sedated
animals (Zimmermann, 1983), and approved by the animal
care and use committee from the Federal University of
Minas Gerais (protocol number 28/2007).
2.2. Drugs
The venomwas obtained by electrical stimulation of the
bees. The apparatus used in this procedure consists of
a pulse generator and 10 glass-collecting plates. Each
apparatus was installed at the hive entrance, in such a way
that the bees were induced (electrical stimulus voltage was
415–420 V) to sting the plate, thus releasing the venom
over its surface. The bees survive after this procedure. AMV
was harvested in amber ﬂasks, dissolved in ammonium
formate (0.1 mol/l, pH 6.8) and centrifuged at 10 000 g
(30 min, 4 C). The supernatant was lyophilised and kept at
20 C until use. Melittin, mellitin-free AMV and the frac-
tion with molecular mass lower than 10 kDa (F<10) were
obtained according to a previously described method
(Banks et al., 1981). In brief, AMVwas subject to a column of
heparin sepharose and eluted with a linear salt gradient as
described. Melittin eluted as the last fraction and was
separated. The other fractions were pooled accordingly and
used as the venom devoid of melittin or F<10. Concentra-
tions were determined using a modiﬁed Lowry method
(Hartree, 1972). After this procedure, the samples were
lyophilised and kept at 20 C until use.
Scorpion (Tityus serrulatus) venom was obtained by
electrical stimulation of the gland located at the telson, as
described by Nascimento et al. (2005). The venom was
collected in a tube and phosphate-buffered saline (pH 7.4;
0.1 mol/l) was added. The tube was centrifuged
(15 000 g, 10 min) and the supernatant obtained was
used in the experiments. Protein concentration in the
supernatant was determined by a modiﬁed Lowry method
(Hartree, 1972). The fraction of mucous protein that
precipitates during the centrifugation was discarded as it
lacks toxicity (Gomez and Diniz, 1966) and its removal
eases the preparation of solutions. Aliquots were stored at
20 C until use.
Snake (Bothrops jararaca) venomwas kindly donated by
the serpentarium of FUNED. The venom was a pool
obtained from adult specimens by manual extraction,
lyophilised and stored at 20 C.
Dexamethasone 21-phosphate disodium salt (Sigma–
Aldrich, St. Louis, MO, USA), formaldehyde (Carlo Erba,
Milan, Italy), morphine sulphate pentahydrated (Cristália,
São Paulo, Brazil) and phenobarbital (Aventis Pharma, São
Paulo, Brazil) were used.
Solutions for injection were prepared immediately
before the experiments by adding isotonic NaCl. The
volume of subcutaneous (s.c.) injection into the dorsum
was 4ml/kg. The volume of s.c. injection into the dorsum of
the right hind paw was 20 ml.
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formaldehyde
Formaldehyde (0.92% v/v in isotonic saline; 20 ml) was
injected into the dorsum of the right hind paw of mice. Each
mouse was placed under a transparent glass funnel (18 cm
diameter, 15 cm-high) and the amount of time the animal
licked the injectedpawwasdeterminedbetween0and5min
(ﬁrst phase) and 15 and 30 min (second phase) after the
injection of formaldehyde. To evaluate the effects induced by
AMV, F<10,melittin,melittin-freeAMV, venomof T. serrulatus
or venom of B. jararaca on the nociceptive response induced
by formaldehyde, the substances were previously (30 min)
injected s.c. into the dorsum of the animals.
2.4. Evaluation of the nociceptive response induced by AMV,
F<10, melittin, T. serrulatus or B. jararaca venoms
AMV (50 or 100 pg), F<10 (50 or 100 pg), melittin (25 or
50 pg), T. serrulatus (1 pg; Nascimento et al., 2005) or B.
jararaca venom (1 pg; Carneiro et al., 2002; Olivo et al.,
2007), in a volume of 20 ml, were injected s.c. into the
dorsum of the right hind paw of mice. Each mouse was
placed under a transparent glass funnel (18 cm diameter,
15 cm-high) and the amount of time the animal licked the
injected paw was determined between 0 and 30 min after
injection. In one protocol, the effect induced by previous
(30 min) s.c. injection of the AMV into the dorsum of mice
on the nociceptive response induced by the injection of
AMV into the right hind paw was investigated.
2.5. Evaluation of the paw oedema induced by formaldehyde
Paw oedema was measured with a plethysmometer
(Model 7140, Ugo Basile, Comerio, Italy). The basal volume
of the right hind paw was determined before administra-
tion of any drug. After determination of the basal volume,
the animals were divided in the experimental groups in
such a way that the mean volumes of the different groups
were similar. AMV, F<10, melittin or dexamethasone were
administered 30 min before s.c. injection of formaldehyde
(0.92%, 20 ml) into the dorsum of the right hind paw. The
paw volumewas measured at 30 and 60 min after injection
of formaldehyde. The results were presented as the paw
volume changes in relation to the baseline.
2.6. Evaluation of the nociceptive response in the hot-plate
model
Thirty minutes after treatment with AMV, F<10, melittin
or morphine, the animals were placed on a heated (54 C)
metal plate (20  20 cm with 18 cm-high walls). The
latency to lick one of the hind paws or to jump off the plate
was determined. Mice were removed from the hot-plate
immediately after the response. The cut off timewas 30 s to
avoid tissue damage.
2.7. Evaluation of the motor activity in the rota-rod
The motor activity of the animals was evaluated in
a rota-rod apparatus. The day before the experiment, theanimals were trained in the apparatus. On the testing day,
the animals were placed on a rotating rod (20 rpm) and the
time they spent on the apparatus was measured. The cut off
time was 2 min (Miyamoto, 2006). After determination of
the baseline values, the animals were treated with the
AMV, F<10, melittin or phenobarbital and 30 min later they
were again tested on the rotating rod.
2.8. Statistical analysis
The results, presented as mean  standard error mean
(S.E.M.), were analyzed by one-way analysis of variance
(ANOVA) followed by Newman–Keuls post-hoc test when
the main effect was signiﬁcant. A P < 0.05 was considered
signiﬁcant. The software Graph Pad Prism 4.0 (San Diego,
CA, USA) was used to perform the analyses.
3. Results
S.c. injection of formaldehyde induced an immediate
nociceptive response characterised by licking the injected
paw. Previous (30 min) s.c. administration of AMV (2, 4 or
6 mg/kg; Fig. 1A), F<10 (4 or 6 mg/kg; Fig. 1B) or melittin (2
or 3 mg/kg; Fig. 1C) into the dorsum of mice inhibited the
nociceptive response.Whereas AMV inhibited both the ﬁrst
and the second phases, F<10 and melittin inhibited only the
second phase. Clearly, the second phase of the nociceptive
response was inhibited by AMV to a greater extent than the
ﬁrst phase (maximum inhibitions of the ﬁrst and second
phases were 44 and 82%, respectively). However, neither
the ﬁrst nor the second phase of this response was
inhibited by previous (30 min) s.c. administration of T.
serrulatus (1 pg; Fig. 1D) or B. jararaca (1 pg; Fig. 1E) venom
into the dorsum of mice.
Exposure of mice to the hot-plate induced a nociceptive
response characterised by ticking or licking the paws and
also jumping off the plate a few seconds later. Previous
(30 min) s.c. administration of AMV (4 or 6 mg/kg; Fig. 2A)
or morphine (10 mg/kg; Fig. 2A)da positive con-
troldincreased the latency of mice to display the noci-
ceptive response in the hot-plate model. However, the
latency to display this response was not increased when
themice were previously (30min) treatedwith F<10 (2, 4 or
6 mg/kg, s.c.; Fig. 2B) or melittin (3 mg/kg, s.c.; Fig. 2C).
Previous (30 min) s.c. administration of AMV (6 mg/kg),
F<10 (6 mg/kg) or melittin (3 mg/kg) into the dorsum of
mice did not alter the time spent by the animals on the
rotating rod, evaluated during 120 s. The latency to fall of
the animals treated with vehicle, AMV, F<10 and melittin
were 120  0, 120  0, 120  0, 118.8  1.2 s, respectively.
However, a marked impairment of their performance was
observed 30 min after s.c. administration of phenobarbital
(50 mg/kg), a positive control (4.3  0.8 s).
S.c. injection of AMV (50 or 100 pg; Fig. 3A), F<10 (50 or
100 pg; Fig. 3A), melittin (25 or 50 pg; Fig. 3A), T. serrulatus
(1 pg; Fig. 3B) or B. jararaca (1 pg; Fig. 3B) venom into the
hind paw of mice induced an immediate nociceptive
response characterised by licking the injected paw. The
nociceptive response induced by F<10 was more intense
than that induced by AMV or melittin. Fig. 4 shows that
previous (30min) s.c. administration of AMV (2 or 4mg/kg)
Fig. 1. Effect induced by previous (30 min) s.c. administration of (A) AMV (2, 4 or 6 mg/kg), (B) F<10 (2, 4 or 6 mg/kg), (C) melittin (1, 2 or 3 mg/kg), (D) Tityus
serrulatus venom (1 pg) or (E) Bothrops jararaca venom (1 pg) into the dorsum of mice on the nociceptive response induced by formaldehyde (0.92%, 20 m1, s.c.)
injected into the dorsum of the right hind paw. *P < 0.05 compared with the vehicle-treated group, tested by ANOVA followed by Newman–Keuls post-hoc test.
Data are expressed as mean  S.E.M. (n ¼ 7–8).
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induced by the AMV (100 pg) injected into the hind paw.
Fig. 5 shows that injection of formaldehyde (0.92%,
20 ml, s.c.) into the hind paw of mice, in addition to inducing
a immediate nociceptive response, induced a marked
oedema that also developed quickly. Surprisingly, the
oedema induced by formaldehyde was not inhibited by
previous (30 min) treatment with dexamethasone (2 mg/
kg), but was inhibited by AMV. Previous (30min) treatment
with F<10 (6 mg/kg) or melittin (3 mg/kg) also failed to
inhibit the oedema.
Next, the contribution of melittin, the main component
of AMV, to its antinociceptive activity was investigated.Previous (30 min) s.c. administration of the melittin-free
AMV also induced an antinociceptive effect (Fig. 6). Doses
ranging from 1 to 4 mg/kg inhibited both phases of the
nociceptive response induced by formaldehyde. Similar to
what was observed for AMV,melittin-free AMV inhibited to
a greater extent the second phase of the nociceptive
response induced by formaldehyde.
4. Discussion
The present study demonstrated that AMV, F<10 and
melittin present antinociceptive activity in experimental
models of nociceptive and inﬂammatory pain. The results
Fig. 2. Effect induced by previous (30 min) s.c. administration of (A) AMV (2, 4 or 6 mg/kg), (B) F<10 (2, 4 or 6 mg/kg), (C) melittin (3 mg/kg) or morphine (10 mg/
kg) into the dorsum of mice on the nociceptive response induced by heat in the hot-plate model. *P < 0.05 compared with the vehicle-treated group, tested by
ANOVA followed by Newman–Keuls post-hoc test. Data are expressed as mean  S.E.M. (n ¼ 7–8).
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different mechanisms, contribute to its antinociceptive
activity.
Initially, we observed that the AMV inhibits both phases
of the nociceptive response induced by formaldehyde. TheFig. 3. Paw licking behaviour evaluated during 30 min after injection of (A) AMV (5
Tityus serrulatus venom (1 pg/paw) or Bothrops jararaca venom (1 pg/paw) into the
treated group, tested by ANOVA followed by Newman–Keuls post-hoc test. Data arﬁrst phase of this response is associated with direct acti-
vation by formaldehyde of transient receptor potential
ankyrin (TRPA)-1 receptors which are present in noci-
ceptors (McNamara et al., 2007). The second phase of this
nociceptive response, markedly inhibited by anti-0 or 100 pg/paw), F<10 (50 or 100 pg/paw) or melittin (25 or 50 pg/paw), (B)
dorsum of the right hind paw of mice. *P < 0.05 compared with the vehicle-
e expressed as mean  S.E.M. (n ¼ 7–8).
Fig. 4. Effect induced by previous (30 min) s.c. administration of AMV (2 or
4 mg/kg) into the dorsum of mice on the paw licking behaviour induced by
s.c. injection of AMV (100 pg) into the dorsum of the right hind paw of mice.
*P < 0.05 compared with the vehicle-treated group, tested by ANOVA fol-
lowed by Newman–Keuls post-hoc test. Data are expressed as mean  S.E.M.
(n ¼ 7–8).
L.A. Merlo et al. / Toxicon 57 (2011) 764–771 769inﬂammatory drugs (Tjolsen et al., 1992), is associated with
stimulation of TRPA1 (McNamara et al., 2007) and also with
the development of an inﬂammatory response triggered by
many mediators such as interleukin (IL)-1b, IL-6, IL-8 and
tumour-necrosis factor (TNF)-a (Chichorro et al., 2004),
eicosanoids and NO (Hunskaar and Hole, 1987; Moore et al.,
1991). As AMV inhibits both phases of the nociceptive
response induced by formaldehyde, it shows a mixed
proﬁle resembling that of drugs that inhibit the central
processing of the nociceptive response or directly reduces
the excitability of nociceptors and also that of drugs that
induce their effects through inhibition of production or
action of different inﬂammatory mediators.
The demonstration of the antinociceptive activity of
AMV is in line with the demonstrations that AMV inhibits
the nociceptive response induced by formaldehyde in mice
(Roh et al., 2006) and rats (Kim et al., 2005). In these
studies, AMV was injected into speciﬁc points of
acupuncture. As the doses (0.08–10 mg/kg) used by theseFig. 5. Effect induced by previous (30 min) s.c. administration of AMV
(6 mg/kg), F<10 (6 mg/kg), melittin (3 mg/kg) or dexamethasone (2 mg/kg)
on the oedema induced by injection of formaldehyde (0.92%, 20 ml, s.c.) into
the dorsum of the right hind paw in mice. *P < 0.05 compared with the
vehicle-treated group, tested by ANOVA followed by Newman–Keuls post-
hoc test. Data are expressed as mean  S.E.M. (n ¼ 7–8).authors are in the range of those used in the present study,
it is suggested that the antinociceptive effect induced by
AMV is not related to injection into a speciﬁc point of
acupuncture, but results from a systemic action.
AMV also presented an antinociceptive activity in the
hot-plate model, as it increased the latency for the display
of the nociceptive response. The nociceptive response in
this model is inhibited by drugs that inhibit the central
nociceptive processing, such as opioids (Loh et al., 1976),
tricyclic antidepressants (Rosland et al., 1988) and anti-
seizure drugs (Mesdjian et al., 1983). The antinociceptive
activity of AMV in this model provides further support to
the inhibition of the ﬁrst phase of the nociceptive response
induced by formaldehyde and also to the suggestion that
such activity, at least in part, may not involve inhibition of
production or action of inﬂammatory mediators.
F<10 andmelittin inhibited the second phase, but not the
ﬁrst phase, of the nociceptive response induced by form-
aldehyde. These results are in linewith the observation that
both F<10 and melittin failed to increase the latency for the
nociceptive response in the hot-plate model. Such results
indicate the F<10 and melittin present an activity that
resembles more that of anti-inﬂammatory drugs and less
that of centrally acting drugs. It has been shown that
melittin inhibits the activation of PLA2 and the production
of inﬂammatory mediators such as NO and other reactive
oxygen species, prostaglandin E2 and inﬂammatory cyto-
kines (Moon et al., 2007; Park et al., 2004; Saini et al., 1997;
Somerﬁeld et al., 1986). Altogether, the effects induced by
AMV, F<10 and melittin in the two nociceptive models used
in the present study indicate that the AMV contains
components that induce an antinociceptive effect as
a result of activation of different mechanisms. It is unlikely
that lack of motor coordination or muscle relaxation
contribute to the antinociceptive activity of the AMV or its
components, as they did not change the time which mice
spent on the rotating rod.
As our results and other already published provide
evidence that part of the antinociceptive activity of the
AMV may be associated with inhibition of the production
or action of inﬂammatory mediators, we investigated if the
AMV, F<10 and melittin, in addition to inhibiting the noci-
ceptive responses induced by formaldehyde, also inhibited
the oedema induced by this inﬂammatory stimulus. It was
observed that the AMV, but not the F<10 or melittin,
inhibited the oedema induced by formaldehyde. These
results indicate that the antinociceptive activity of AMV
may be at least in part related to an anti-inﬂammatory
effect. In addition, they provide evidence that components
of molecular mass higher than 10 kDa contribute more
effectively to this effect. Clearly, AMV contains different
components presenting antinociceptive and anti-inﬂam-
matory activities. It seems that components withmolecular
mass higher than 10 kDa are essential for the antioedema,
but not for the antinociceptive activity.
To the best of our knowledge, this is the ﬁrst demon-
stration of the antinociceptive activity of melittin. This
result leads to the suggestion that melittin, the main
component of AMV, may contribute to the antinociceptive
activity of both AMV and F<10. However, the melittin-free
AMV also inhibited the nociceptive response induced by
Fig. 6. Effect induced by previous (30 min) s.c. administration of melittin-
free AMV (MFAMV; 1, 2 or 4 mg/kg) into the dorsum of mice on the noci-
ceptive response induced by formaldehyde (0.92% v/v, 20 ml, s.c.) injected
into the dorsum of the right hind paw. *P < 0.05 compared with the vehicle-
treated group, tested by ANOVA followed by Newman–Keuls post-hoc test.
Data are expressed as mean  S.E.M. (n ¼ 7–8).
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nociceptive activity, it is not the only component that
contributes to the antinociceptive activity of AMV.
The demonstration that melittin induces two contrast-
ing effects, nociception (present study, Chen et al., 2006; Li
and Chen, 2004; Mackler and Kreil, 1977; Sumikura et al.,
2006) and antinociception (present study), adds to the
results showing that AMV also presents such proﬁle.
Convincing evidence that AMV presents such proﬁle was
obtained in the protocol in which AMV, administered into
the dorsum (s.c. injection) of the animals, inhibited the
nociceptive response induced by the same AMV injected
into the dorsum of the paw.
As the s.c. injection of AVM into the dorsum of the
animals probably induces a discomfort, it is possible that its
antinociceptive activity results from a non-speciﬁc activa-
tion of endogenous antinociceptive mechanisms associated
with the previous exposure to a noxious stimulus. Anti-
nociception associatedwith exposure to stimuli that induce
discomfort and pain is widely known and multiple mech-
anisms have been proposed to explain such phenomenon
(Gebhart, 2004). To explore this possibility, we evaluated
the effects induced by venoms obtained from other species,
T. serrulatus and B. jararaca. These venoms induced a noci-
ceptive response, as already reported (Carneiro et al., 2002;
Olivo et al., 2007). However, these venoms did not inhibit
the nociceptive response induced by formaldehyde. These
results clearly indicate that the antinociceptive activity of
AMV, F<10 and melittin does not result from a non-speciﬁc
activation of endogenous antinociceptive mechanisms, but
from the action of different components that speciﬁcally
inhibit the nociceptive processing, both in the periphery
and in the central nervous system.
Concluding, the present study demonstrated that AMV,
F<10 and melittin induce two contrasting effects: noci-
ception and antinociception. Althoughmelittin exhibits an
antinociceptive activity, it is not the only component that
contributes to the antinociceptive activity of AMV. The
antinociceptive activity of the AMV does not result from
a non-speciﬁc activation of endogenous antinociceptivemechanisms associated with the exposure to noxious
stimuli. Different components of the AMV contribute to
the inhibition of the nociceptive response and oedema.
The knowledge of the pharmacological properties of the
AMV and its components may allow the development of
more effective treatment of inﬂammatory and painful
disorders, as well as the discovery of new pharmacological
tools.
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